Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from...
Mr. Chardon is a recognized commercialization expert with a successful track record in new category creation in the health & wellness industry ...
Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Record-high PPU Growth of +109%1 in Q4 2023, Full Year PPU Growth of +57%1 Tasly and Telix Partnerships Remain On-Track Partnership Pipeline...
Builds on existing research collaboration for precision surgery in urology Telix Pharmaceuticals to acquire a ~19% stake in Mauna Kea Technologies...
Ongoing enrollment of over 200 patients across 7 sites in Europe and the U.S. Paris and Boston, November 2, 2023 – 08:00 a.m. CET...
Strong performance thanks to partnership revenue and U.S. growth +40% increase in Q3 U.S. PPU revenue Strong convergence of current and upcoming...
Confocal Laser Endomicroscopy with Cellvizio proven superior to X-ray fluoroscopy for the guidance of transbronchial cryobiopsy, offering a...
Strong H1 sales growth (+101%) and significant reduction in current operating loss (-78%) Generated YTD net profit, supported by contribution...
Dr. Jeong Kim Uses Cellvizio to Improve Diagnosis of Gastric Disease Paris and Boston, September 19, 2023 – 8:00 a.m. CEST – Mauna Kea...
Paris and Boston, August 4, 2023 – 8:00 a.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Q2 revenue increased 77% globally, including 100% United States sales growth Pipeline of new potential strategic partnerships continues to...
